Patient P-03300

Synthetic patientONX-7 · Day 150 · 35–44 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Favorable

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S14
Day 60 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 69 GI-04 recommended — GI Support Protocol GI-04
Day 70 Patient accepted — Started GI-04 in the companion
Day 78 GI symptom burden −38% vs expected — GI Support Protocol GI-04
Day 84 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 60.

Primary contributors, last 14 days

GI instability+13
Inflammatory activity+5
Nutritional resilience-4

What helped?

GI Support Protocol GI-04Day 69
Result: symptom burden −38%

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

70%

probability of meaningful tolerance improvement

284 similar trajectories
80% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 47 and rising
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 41
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 40/100
Autonomic recovery ↓25
- WearableResting HR 74 bpm

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 40/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 46 ms
Sleep: 6.8 h
Steps: 6,657
Resting HR: 72 bpm

Daily log: GI score 47, nutritional resilience 52, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03070	52%	S14	GI-04	improved	51
P-03090	51%	S02	GI-04	improved	48
P-03146	49%	S14	GI-04	improved	53
P-03110	46%	S15	GI-04	improved	52
P-03159	46%	S14	GI-04	improved	37
P-03145	44%	S14	GI-04	improved	51
P-03123	42%	S14	GI-04	improved	50
P-03226	42%	S05	GI-04	improved	43
P-03225	37%	S19	GI-04	improved	50
P-03323	37%	S14	GI-04	improved	48
P-03430	37%	S14	SC-12	improved	45
P-03037	35%	S14	NP-02	improved	43